| × | | --- | | 第一章 | 总则 | 1 | | --- | --- | --- | | 第二章 | 经营宗旨和范围 | 2 | | 第三章 | 股份 | 3 | | 第一节 | 股份发行 | 3 | | 第二节 | 股份增减和回购 | 4 | | 第三节 | 股份转让 | 6 | | 第四章 | 股东和股东会 | 6 | | 第一节 | 股东 | 6 | | 第二节 | 控股股东和实际控制人 | 9 | | 第三节 | 股东会的一般规定 | 10 | | 第四节 | 股东会的召集 | 13 | | 第五节 | 股东会的提案与通知 | 15 | | 第六节 | 股东会的召开 | 16 | | 第七节 | 股东会的表决和决议 | 19 | | 第五章 | 董事和董事会 | 23 | | 第一节 | 董事的一般规定 | 23 | | 第二节 | 董事会 | 27 | | 第三节 | 独立董事 | 31 | | 第四节 | 董事会专门委员会 | 34 | | 第六章 | 高级管理人员 | 36 | | 第七章 | 财务会计制度、利润分配和审计 | 38 | | 第一节 | 财务会计制度及利润分配 | ...

2025 年 4 月 28 日 此外，上述独立董事候选人具有丰富的专业知识，熟悉相关法律、行政法规、规 章与规则，其任职资格、教育背景、工作经历、业务能力符合公司独立董事任职要求。 其中王晶女士是会计专业人士，并具备注册会计师资格、高级会计师职称。 因此，我们同意提名孔东升先生、吴保元先生、王晶女士为第四届董事会独立董 事候选人。并同意提请公司董事会和股东大会予以审议。 邦彦技术股份有限公司 董事会提名委员会 邦彦技术股份有限公司董事会提名委员会 关于第四届董事会独立董事候选人的审查意见 根据《中华人民共和国公司法》（以下简称"《公司法》"）《上市公司独立董事管 理办法》（以下简称"《管理办法》"）《上海证券交易所上市公司自律监管指引第 1 号——规范运作》等法律、法规以及《邦彦技术股份有限公司章程》（以下简称"《公 司章程》"）的有关规定，邦彦技术股份有限公司（以下简称"公司"）第三届董事会 提名委员会对拟提交公司董事会审议的《关于董事会换届选举暨提名第四届董事会独 立董事候选人的议案》进行了审议，经对独立董事候选人的简历和相关资料进行审查， 发表如下审查意见： 经审查孔东升先生、吴保元先生、王晶女士的个人 ...

邦彦技术股份有限公司 董事会审计委员会工作细则 邦彦技术股份有限公司 董事会审计委员会工作细则 第一章 总则 第一条 为强化邦彦技术股份有限公司（以下简称"公司"）董事会决策功 能，加强公司董事会对管理层有效监督，完善公司治理结构，根据《中华人民共 和国公司法》（以下简称"《公司法》"）《上市公司治理准则》《上市公司独 立董事管理办法》《邦彦技术股份有限公司章程》（以下简称"《公司章程》"） 及其他有关法律、行政法规和规范性文件，公司设董事会审计委员会，并制定本 工作细则。 第二条 审计委员会委员应保证足够的时间和精力履行委员会的工作职责， 勤勉尽责，切实有效地监督公司的外部审计，指导公司内部审计工作，促进公司 建立有效的内部控制并提供真实、准确、完整的财务报告。 第二章 人员组成 第三条 审计委员会由3名董事组成，审计委员会成员应当为不在公司担任 高级管理人员的董事，其中独立董事应当过半数，公司董事会成员中的职工代表 可以成为审计委员会成员。 第四条 审计委员会委员由董事长、1/2以上独立董事或者全体董事的1/3以上 提名，并由董事会选举产生。 第五条 审计委员会设主任委员一名作为委员会召集人，由独立董事中 ...

Financial Performance - The company reported a basic earnings per share of -0.1800 yuan for Q1 2025, a decrease of 175% compared to 0.2400 yuan in Q1 2024 [1] - The net profit for Q1 2025 was -0.27 billion yuan, representing a decline of 177.14% from 0.35 billion yuan in Q1 2024 [1] - The operating revenue for Q1 2025 was 0.28 billion yuan, down 78.13% from 1.28 billion yuan in Q1 2024 [1] - The return on equity for Q1 2025 was -1.88%, a significant drop of 182.46% compared to 2.28% in Q1 2024 [1] Shareholder Information - The top ten unrestricted shareholders collectively hold 46.8994 million shares, accounting for 43.22% of the circulating shares, with a slight decrease of 0.10 million shares from the previous period [2] - The largest shareholder, Jinpai Co., Ltd., holds 23.40 million shares, representing 21.57% of the total share capital, with no change [3] - Other notable shareholders include Shenzhen Zhongyan Innovation Investment Partnership and Shenzhen Innovation Investment Group, holding 6.3255 million shares (5.83%) and 2.797 million shares (2.58%) respectively, both unchanged [3] Dividend Policy - The company has announced that it will not distribute dividends or transfer shares this time [4]

证券代码：688132 证券简称：邦彦技术 公告编号：2025-023 2024年12月2日，公司召开第三届董事会第二十四次会议、第三届监事会第 二十二次会议，审议通过了《关于公司本次发行股份及支付现金购买资产并募 集配套资金暨关联交易方案的议案》《关于公司本次发行股份及支付现金购买 资产并募集配套资金暨关联交易预案及其摘要的议案》等与本次交易相关的议 案，具体内容详见公司同日在上海证券交易所网站（www.sse.com.cn）披露的 相关公告。 关于发行股份及支付现金购买资产并募集配套资金 暨关联交易的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、本次交易的基本情况 邦彦技术股份有限公司（以下简称"公司"）拟通过发行股份及支付现金的 方式购买深圳星网信通科技股份有限公司100%的股份，同时募集配套资金（以 下简称"本次交易"）。 经公司向上海证券交易所申请，公司股票（股票简称：邦彦技术，证券代 码：688132）自2024年11月25日开市起停牌，具体内容详见公司于2024年11月 25日、2024年11 ...

Investment Rating - The report maintains a "Strong Buy" rating for the company, expecting it to outperform the benchmark index by over 20% in the next six months [1][19]. Core Views - The company achieved a revenue of 347 million yuan in 2024, representing a year-on-year growth of 91.98%. However, it reported a net loss attributable to shareholders of 36.61 million yuan, an improvement from a loss of 52.25 million yuan in the previous year [1][4]. - The growth in the ship communication business is robust, with revenue reaching 280 million yuan, a staggering increase of 355.47% year-on-year. The company is also expanding into civilian products, leveraging its expertise in domestic self-control and information security [8]. - The company plans to acquire 100% of Xingwang Xintong, which is expected to enhance business synergy and accelerate growth. The acquisition includes a performance commitment of at least 180 million yuan in net profit over three years [8]. Financial Summary - For 2024, the total revenue is projected at 347 million yuan, with a growth rate of 92.0%. The net profit attributable to shareholders is expected to improve to a profit of 74 million yuan by 2025, with corresponding EPS of 0.48 yuan [4][8]. - The company’s total assets are estimated to grow from 1.716 billion yuan in 2024 to 2.325 billion yuan by 2027, indicating a strong upward trend in financial health [9]. - The company’s market capitalization is currently 2.918 billion yuan, with a circulating market value of 2.080 billion yuan [5].

Regulatory Developments - The National Medical Products Administration reported four cases of illegal online sales of medical devices, emphasizing a "zero tolerance" regulatory attitude to ensure safety in medical device usage [2] - Companies involved include Jiangyin Tianyu Medical Device Co., Yiwu Shenghe Medical Device Co., Shanghai Yile Warehouse Medical Device Co., and Hefei Baohua Design Studio, all of which failed to comply with regulatory requirements [2] Industry Advancements - Hangzhou is accelerating the development of medical artificial intelligence applications, aiming to establish a national AI (medical) application pilot base and create intelligent medical entities focused on various health management areas [3] - The city plans to build digital health innovation laboratories to advance key technologies in medical AI [3] Company Announcements - Leksin Medical received a medical device registration certificate for its wrist-type electronic blood pressure monitor from the Guangdong Provincial Drug Administration [5] - David Medical's wholly-owned subsidiary, Ningbo Yongxing Medical Instruments Co., obtained a medical device registration certificate for a linear cutting stapler used in various surgical procedures [6] - Warner Pharmaceuticals announced the approval of its drug registration certificate for the injection of methoxamine hydrochloride, used for treating acute hypotension during spinal anesthesia [7] Financial Reports - Guobang Pharmaceutical reported a revenue of 1.44 billion yuan for Q1 2025, a year-on-year increase of 7.57%, with a net profit of 215 million yuan, up 8.17% [9] - Johnson & Johnson's Q1 sales reached 21.89 billion dollars, with an annual sales forecast of 91 to 91.8 billion dollars and adjusted earnings per share projected between 10.50 and 10.70 dollars [10] Market Movements - In Hong Kong, InnoCare's stock surged by 130% on its first trading day [12] - Darentang announced plans to transfer a 12% stake in China-US Tianjin Schering Pharmaceutical Co., with estimated investment income of approximately 1.54 billion yuan from the transaction [13] - Nanjing Noling Biotechnology completed a C-round financing of several hundred million yuan, led by Dingxin Capital [14] Collaborative Initiatives - Berry Genomics' subsidiary signed a project cooperation framework agreement with Beijing Children's Hospital to promote clinical transformation and commercialization of research outcomes related to newborn screening technologies [16] - Bangyan Technology plans to officially launch its AI Agent product this year, aimed at assisting digital transformation in the healthcare sector [17] Personnel Changes - Bell Bio's financial officer, Zhao Baozhen, resigned for personal reasons but will continue to serve as the board secretary [19]

Summary of Conference Call Company and Industry - The conference call discusses a company involved in the development of AI Agents and cloud PC products, indicating a focus on digital transformation and innovation in the technology sector. Key Points and Arguments 1. **AI Agent Development**: The company is integrating AI Agents with cloud PC products, aiming for significant breakthroughs in digital employee solutions, which are expected to enhance operational efficiency for businesses [1][3][4]. 2. **Market Recovery**: There are signs of recovery in the military sector, which the company anticipates will benefit from increased military spending and demand for its products [2][18]. 3. **Product Differentiation**: The cloud PC product is positioned as a solution that overcomes the limitations of traditional virtual desktop infrastructure (VDI) by providing a more efficient and secure computing environment [5][6][7]. 4. **Market Size and Potential**: The commercial PC market is estimated to be around 200 billion yuan, with the company targeting a significant share, especially in sectors requiring high security and performance [15][16]. 5. **Business Model**: The AI Agent product will be available for both B2B and B2C markets, with revenue generated through project-based fees for custom solutions and usage-based fees for standard services [11][22]. 6. **Competitive Landscape**: The company acknowledges competition from major players in the digital employee space but believes it has unique advantages in specific applications and customer segments [10][12]. 7. **Regulatory Compliance**: The cloud PC product is expected to receive national security certifications, which will open up procurement opportunities in sensitive sectors such as government and military [16][19]. 8. **Future Outlook**: The company is optimistic about its growth trajectory, with expectations of significant revenue from both military and commercial sectors, projecting a total revenue of around 600 million yuan for the year [19][33]. Other Important Content - **Technological Integration**: The AI Agent is designed to enhance traditional products by adding intelligent features, which will improve operational capabilities in various sectors, including military applications [24][30]. - **Customer Engagement**: The company is actively engaging with potential clients, including government and enterprise sectors, to facilitate product trials and feedback, which is crucial for contract conversions [26][27]. - **Investment Opportunities**: The company encourages investors to explore its innovative solutions and potential market impact, highlighting the importance of understanding the evolving technology landscape [34]. This summary encapsulates the main themes and insights from the conference call, providing a comprehensive overview of the company's strategic direction and market positioning.

Investment Rating - The report gives a "Strong Buy" rating for the company [2] Core Views - The company is undergoing a transformation driven by military and technology sectors, focusing on midstream manufacturing and military applications [1] - The company has faced performance pressure in recent years due to customer delivery schedules, but acquisitions may improve its performance [7] - The cloud computing sector is thriving, and the company's cloud PC product is positioned to capitalize on this trend [7] - The AI business is expected to take off in 2025, with applications across various industries [7] - The company aims to leverage its military-grade quality to tap into the B-end and G-end information security markets [7] - The proposed acquisition of Xingwang Xintong is expected to enhance market access and product offerings [7][8] Summary by Sections Company Overview - Founded in April 2000, the company specializes in the R&D, manufacturing, sales, and service of information communication and security devices [1][14] - The company has received numerous awards for its technological advancements and contributions to military communication [14] Business Segments - The company has a dual growth strategy focusing on military products and expanding into civilian markets, including cloud PC and AI Agent products [21][39] - Military business segments include fusion communication, ship communication, and information security, while civilian products focus on distributed audio-visual control systems and cloud computing solutions [21][39] Financial Performance - The company experienced a 51.18% decline in revenue in 2023 due to delivery delays, but expects significant growth in 2024 [7][44] - The forecasted net profit for 2025-2027 is projected to be 0.55 billion, 0.81 billion, and 1.17 billion respectively, with corresponding P/E ratios of 55, 37, and 26 [8] Market Opportunities - The military communication sector is expected to benefit from ongoing national defense spending and modernization efforts [55][66] - The company is well-positioned to capture growth in the information security market, driven by increasing demand for secure communication solutions [7][55] Acquisition Strategy - The acquisition of Xingwang Xintong is anticipated to create synergies and expand the company's reach into government and enterprise markets [7][8][47]

邦彦技术股份有限公司 2024 年年度股东大会会议资料 证券代码：688132 证券简称：邦彦技术 2024 年年度股东大会 会议资料 2024 年 4 月 邦彦技术股份有限公司 2024 年年度股东大会会议资料 目 录 | 2024 | 年年度股东大会会议须知 | 1 | | --- | --- | --- | | 2024 | 年年度股东大会会议议程 | 3 | | 2024 | 年年度股东大会会议议案 | 5 | 邦彦技术股份有限公司 2024 年年度股东大会会议资料 邦彦技术股份有限公司 2024 年年度股东大会会议须知 为维护广大投资者的合法权益，保障股东在本次股东大会期间依法行使权利， 根据《公司法》、中国证监会《上市公司股东大会规则》和公司《股东大会议事 规则》等有关规定，特制定本会议须知： 一、公司负责本次股东大会的议程安排和会务工作,为确认出席大会的股东 或其代理人或其他出席者的出席资格，会议工作人员将对出席会议者的身份进行 必要的核对工作，请被核对者给予配合。 二、出席会议的股东及股东代理人须在会议召开前半小时到会议现场办理签 到手续，并按规定出示证券账户卡、身份证明文件或营业执照/注册证 ...